nodes	percent_of_prediction	percent_of_DWPC	metapath
Toremifene—ESR1—urinary bladder cancer	0.542	1	CbGaD
Toremifene—ABCB1—Mitomycin—urinary bladder cancer	0.0843	0.317	CbGbCtD
Toremifene—CYP3A4—Thiotepa—urinary bladder cancer	0.0383	0.144	CbGbCtD
Toremifene—ABCB1—Gemcitabine—urinary bladder cancer	0.0243	0.0912	CbGbCtD
Toremifene—CYP1A2—Fluorouracil—urinary bladder cancer	0.0237	0.0892	CbGbCtD
Toremifene—CYP1A2—Etoposide—urinary bladder cancer	0.0198	0.0745	CbGbCtD
Toremifene—ABCB1—Cisplatin—urinary bladder cancer	0.0176	0.0663	CbGbCtD
Toremifene—ABCB1—Etoposide—urinary bladder cancer	0.0173	0.0651	CbGbCtD
Toremifene—ABCB1—Doxorubicin—urinary bladder cancer	0.0118	0.0444	CbGbCtD
Toremifene—ABCB1—Methotrexate—urinary bladder cancer	0.0114	0.043	CbGbCtD
Toremifene—CYP3A4—Etoposide—urinary bladder cancer	0.0104	0.039	CbGbCtD
Toremifene—CYP3A4—Doxorubicin—urinary bladder cancer	0.00708	0.0266	CbGbCtD
Toremifene—CYP1A2—urine—urinary bladder cancer	0.00206	0.152	CbGeAlD
Toremifene—CYP3A4—urine—urinary bladder cancer	0.00149	0.11	CbGeAlD
Toremifene—Benzphetamine—POR—urinary bladder cancer	0.0012	0.378	CrCbGaD
Toremifene—ESR1—prostate gland—urinary bladder cancer	0.00096	0.0709	CbGeAlD
Toremifene—Ospemifene—ESR1—urinary bladder cancer	0.00077	0.243	CrCbGaD
Toremifene—ESR1—epithelium—urinary bladder cancer	0.000706	0.0521	CbGeAlD
Toremifene—ESR1—smooth muscle tissue—urinary bladder cancer	0.00068	0.0502	CbGeAlD
Toremifene—ESR1—renal system—urinary bladder cancer	0.000655	0.0483	CbGeAlD
Toremifene—Clomifene—ESR1—urinary bladder cancer	0.000543	0.171	CrCbGaD
Toremifene—CYP1A1—epithelium—urinary bladder cancer	0.000537	0.0396	CbGeAlD
Toremifene—ESR1—female reproductive system—urinary bladder cancer	0.000524	0.0387	CbGeAlD
Toremifene—CYP1A2—renal system—urinary bladder cancer	0.000505	0.0372	CbGeAlD
Toremifene—CYP1A1—renal system—urinary bladder cancer	0.000498	0.0367	CbGeAlD
Toremifene—CYP1A1—urethra—urinary bladder cancer	0.000489	0.0361	CbGeAlD
Toremifene—ESR1—vagina—urinary bladder cancer	0.000474	0.035	CbGeAlD
Toremifene—Tamoxifen—ESR2—urinary bladder cancer	0.000407	0.129	CrCbGaD
Toremifene—CYP1A1—female reproductive system—urinary bladder cancer	0.000399	0.0294	CbGeAlD
Toremifene—ABCB1—prostate gland—urinary bladder cancer	0.000379	0.028	CbGeAlD
Toremifene—CYP3A4—renal system—urinary bladder cancer	0.000365	0.027	CbGeAlD
Toremifene—CYP1A1—vagina—urinary bladder cancer	0.00036	0.0266	CbGeAlD
Toremifene—ABCB1—seminal vesicle—urinary bladder cancer	0.000321	0.0237	CbGeAlD
Toremifene—ESR1—lymph node—urinary bladder cancer	0.000307	0.0226	CbGeAlD
Toremifene—CYP3A4—female reproductive system—urinary bladder cancer	0.000292	0.0216	CbGeAlD
Toremifene—ABCB1—epithelium—urinary bladder cancer	0.000279	0.0206	CbGeAlD
Toremifene—Vision blurred—Fluorouracil—urinary bladder cancer	0.000265	0.00249	CcSEcCtD
Toremifene—Anorexia—Thiotepa—urinary bladder cancer	0.000265	0.00249	CcSEcCtD
Toremifene—Thrombophlebitis—Epirubicin—urinary bladder cancer	0.000263	0.00247	CcSEcCtD
Toremifene—Eye disorder—Etoposide—urinary bladder cancer	0.000262	0.00247	CcSEcCtD
Toremifene—ABCB1—renal system—urinary bladder cancer	0.000259	0.0191	CbGeAlD
Toremifene—Leukopenia—Gemcitabine—urinary bladder cancer	0.000256	0.00241	CcSEcCtD
Toremifene—Angiopathy—Etoposide—urinary bladder cancer	0.000255	0.00239	CcSEcCtD
Toremifene—ABCB1—urethra—urinary bladder cancer	0.000254	0.0187	CbGeAlD
Toremifene—Mediastinal disorder—Etoposide—urinary bladder cancer	0.000253	0.00238	CcSEcCtD
Toremifene—Abnormal vision—Doxorubicin—urinary bladder cancer	0.000253	0.00238	CcSEcCtD
Toremifene—Chills—Etoposide—urinary bladder cancer	0.000252	0.00237	CcSEcCtD
Toremifene—Leukopenia—Fluorouracil—urinary bladder cancer	0.000252	0.00237	CcSEcCtD
Toremifene—Vision blurred—Cisplatin—urinary bladder cancer	0.000251	0.00236	CcSEcCtD
Toremifene—Tamoxifen—ESR1—urinary bladder cancer	0.000251	0.0792	CrCbGaD
Toremifene—Tremor—Cisplatin—urinary bladder cancer	0.00025	0.00235	CcSEcCtD
Toremifene—Alopecia—Etoposide—urinary bladder cancer	0.000248	0.00233	CcSEcCtD
Toremifene—Lethargy—Methotrexate—urinary bladder cancer	0.000248	0.00233	CcSEcCtD
Toremifene—Chest pain—Gemcitabine—urinary bladder cancer	0.000244	0.00229	CcSEcCtD
Toremifene—Hot flush—Epirubicin—urinary bladder cancer	0.000243	0.00228	CcSEcCtD
Toremifene—Thrombophlebitis—Doxorubicin—urinary bladder cancer	0.000243	0.00228	CcSEcCtD
Toremifene—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—urinary bladder cancer	0.000242	0.00227	CcSEcCtD
Toremifene—Decreased appetite—Thiotepa—urinary bladder cancer	0.000241	0.00227	CcSEcCtD
Toremifene—Menopausal symptoms—Epirubicin—urinary bladder cancer	0.000241	0.00227	CcSEcCtD
Toremifene—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.00024	0.00225	CcSEcCtD
Toremifene—Chest pain—Fluorouracil—urinary bladder cancer	0.00024	0.00225	CcSEcCtD
Toremifene—Fatigue—Thiotepa—urinary bladder cancer	0.000239	0.00225	CcSEcCtD
Toremifene—Leukopenia—Cisplatin—urinary bladder cancer	0.000239	0.00224	CcSEcCtD
Toremifene—Pain—Thiotepa—urinary bladder cancer	0.000237	0.00223	CcSEcCtD
Toremifene—Constipation—Thiotepa—urinary bladder cancer	0.000237	0.00223	CcSEcCtD
Toremifene—Back pain—Etoposide—urinary bladder cancer	0.000236	0.00222	CcSEcCtD
Toremifene—Oedema—Gemcitabine—urinary bladder cancer	0.000234	0.00219	CcSEcCtD
Toremifene—CYP1A1—lymph node—urinary bladder cancer	0.000233	0.0172	CbGeAlD
Toremifene—Cardiac failure—Epirubicin—urinary bladder cancer	0.000233	0.00219	CcSEcCtD
Toremifene—Lethargy—Epirubicin—urinary bladder cancer	0.000232	0.00218	CcSEcCtD
Toremifene—Mood swings—Methotrexate—urinary bladder cancer	0.00023	0.00216	CcSEcCtD
Toremifene—Oedema—Fluorouracil—urinary bladder cancer	0.00023	0.00216	CcSEcCtD
Toremifene—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.000229	0.00215	CcSEcCtD
Toremifene—Thrombocytopenia—Gemcitabine—urinary bladder cancer	0.000229	0.00215	CcSEcCtD
Toremifene—Ataxia—Methotrexate—urinary bladder cancer	0.000229	0.00215	CcSEcCtD
Toremifene—Diplopia—Epirubicin—urinary bladder cancer	0.000228	0.00214	CcSEcCtD
Toremifene—Skin disorder—Gemcitabine—urinary bladder cancer	0.000227	0.00213	CcSEcCtD
Toremifene—Hyperhidrosis—Gemcitabine—urinary bladder cancer	0.000226	0.00212	CcSEcCtD
Toremifene—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.000226	0.00212	CcSEcCtD
Toremifene—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.000225	0.00212	CcSEcCtD
Toremifene—Hot flush—Doxorubicin—urinary bladder cancer	0.000225	0.00211	CcSEcCtD
Toremifene—Thrombocytopenia—Fluorouracil—urinary bladder cancer	0.000225	0.00211	CcSEcCtD
Toremifene—Liver function test abnormal—Methotrexate—urinary bladder cancer	0.000224	0.00211	CcSEcCtD
Toremifene—Affect lability—Epirubicin—urinary bladder cancer	0.000224	0.0021	CcSEcCtD
Toremifene—Menopausal symptoms—Doxorubicin—urinary bladder cancer	0.000223	0.0021	CcSEcCtD
Toremifene—Anorexia—Gemcitabine—urinary bladder cancer	0.000223	0.00209	CcSEcCtD
Toremifene—Breast disorder—Methotrexate—urinary bladder cancer	0.00022	0.00206	CcSEcCtD
Toremifene—Vertigo—Etoposide—urinary bladder cancer	0.00022	0.00206	CcSEcCtD
Toremifene—Anorexia—Fluorouracil—urinary bladder cancer	0.000219	0.00206	CcSEcCtD
Toremifene—Leukopenia—Etoposide—urinary bladder cancer	0.000219	0.00206	CcSEcCtD
Toremifene—Oedema—Cisplatin—urinary bladder cancer	0.000218	0.00205	CcSEcCtD
Toremifene—Cardiac failure—Doxorubicin—urinary bladder cancer	0.000216	0.00203	CcSEcCtD
Toremifene—Mood swings—Epirubicin—urinary bladder cancer	0.000216	0.00202	CcSEcCtD
Toremifene—Lethargy—Doxorubicin—urinary bladder cancer	0.000215	0.00202	CcSEcCtD
Toremifene—Ataxia—Epirubicin—urinary bladder cancer	0.000214	0.00201	CcSEcCtD
Toremifene—Nervous system disorder—Cisplatin—urinary bladder cancer	0.000214	0.00201	CcSEcCtD
Toremifene—Thrombocytopenia—Cisplatin—urinary bladder cancer	0.000213	0.002	CcSEcCtD
Toremifene—Skin disorder—Cisplatin—urinary bladder cancer	0.000211	0.00199	CcSEcCtD
Toremifene—Insomnia—Gemcitabine—urinary bladder cancer	0.000211	0.00199	CcSEcCtD
Toremifene—Diplopia—Doxorubicin—urinary bladder cancer	0.000211	0.00198	CcSEcCtD
Toremifene—Hyperhidrosis—Cisplatin—urinary bladder cancer	0.00021	0.00198	CcSEcCtD
Toremifene—Liver function test abnormal—Epirubicin—urinary bladder cancer	0.00021	0.00197	CcSEcCtD
Toremifene—Dyspnoea—Gemcitabine—urinary bladder cancer	0.000208	0.00196	CcSEcCtD
Toremifene—Chest pain—Etoposide—urinary bladder cancer	0.000208	0.00196	CcSEcCtD
Toremifene—Insomnia—Fluorouracil—urinary bladder cancer	0.000208	0.00195	CcSEcCtD
Toremifene—Anorexia—Cisplatin—urinary bladder cancer	0.000208	0.00195	CcSEcCtD
Toremifene—Affect lability—Doxorubicin—urinary bladder cancer	0.000207	0.00195	CcSEcCtD
Toremifene—ABCB1—female reproductive system—urinary bladder cancer	0.000207	0.0153	CbGeAlD
Toremifene—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.000207	0.00194	CcSEcCtD
Toremifene—Breast disorder—Epirubicin—urinary bladder cancer	0.000206	0.00193	CcSEcCtD
Toremifene—Dyspnoea—Fluorouracil—urinary bladder cancer	0.000205	0.00192	CcSEcCtD
Toremifene—Decreased appetite—Gemcitabine—urinary bladder cancer	0.000203	0.00191	CcSEcCtD
Toremifene—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000202	0.00189	CcSEcCtD
Toremifene—Fatigue—Gemcitabine—urinary bladder cancer	0.000201	0.00189	CcSEcCtD
Toremifene—Constipation—Gemcitabine—urinary bladder cancer	0.0002	0.00188	CcSEcCtD
Toremifene—Pain—Gemcitabine—urinary bladder cancer	0.0002	0.00188	CcSEcCtD
Toremifene—Decreased appetite—Fluorouracil—urinary bladder cancer	0.0002	0.00188	CcSEcCtD
Toremifene—Mood swings—Doxorubicin—urinary bladder cancer	0.000199	0.00187	CcSEcCtD
Toremifene—Asthenia—Thiotepa—urinary bladder cancer	0.000199	0.00187	CcSEcCtD
Toremifene—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000198	0.00186	CcSEcCtD
Toremifene—Ataxia—Doxorubicin—urinary bladder cancer	0.000198	0.00186	CcSEcCtD
Toremifene—Pruritus—Thiotepa—urinary bladder cancer	0.000196	0.00185	CcSEcCtD
Toremifene—Pain—Fluorouracil—urinary bladder cancer	0.000196	0.00185	CcSEcCtD
Toremifene—Thrombocytopenia—Etoposide—urinary bladder cancer	0.000195	0.00183	CcSEcCtD
Toremifene—Liver function test abnormal—Doxorubicin—urinary bladder cancer	0.000194	0.00183	CcSEcCtD
Toremifene—Dyspnoea—Cisplatin—urinary bladder cancer	0.000194	0.00182	CcSEcCtD
Toremifene—Skin disorder—Etoposide—urinary bladder cancer	0.000194	0.00182	CcSEcCtD
Toremifene—Hyperhidrosis—Etoposide—urinary bladder cancer	0.000193	0.00181	CcSEcCtD
Toremifene—Angina pectoris—Epirubicin—urinary bladder cancer	0.000192	0.0018	CcSEcCtD
Toremifene—Breast disorder—Doxorubicin—urinary bladder cancer	0.00019	0.00179	CcSEcCtD
Toremifene—Anorexia—Etoposide—urinary bladder cancer	0.00019	0.00179	CcSEcCtD
Toremifene—Decreased appetite—Cisplatin—urinary bladder cancer	0.000189	0.00178	CcSEcCtD
Toremifene—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000188	0.00177	CcSEcCtD
Toremifene—ABCB1—vagina—urinary bladder cancer	0.000187	0.0138	CbGeAlD
Toremifene—Pain—Cisplatin—urinary bladder cancer	0.000186	0.00175	CcSEcCtD
Toremifene—Dizziness—Thiotepa—urinary bladder cancer	0.000184	0.00173	CcSEcCtD
Toremifene—Sweating—Methotrexate—urinary bladder cancer	0.00018	0.00169	CcSEcCtD
Toremifene—Weight increased—Epirubicin—urinary bladder cancer	0.000179	0.00168	CcSEcCtD
Toremifene—Dyspnoea—Etoposide—urinary bladder cancer	0.000178	0.00167	CcSEcCtD
Toremifene—Angina pectoris—Doxorubicin—urinary bladder cancer	0.000177	0.00167	CcSEcCtD
Toremifene—Hepatobiliary disease—Methotrexate—urinary bladder cancer	0.000177	0.00166	CcSEcCtD
Toremifene—Vomiting—Thiotepa—urinary bladder cancer	0.000177	0.00166	CcSEcCtD
Toremifene—Rash—Thiotepa—urinary bladder cancer	0.000175	0.00165	CcSEcCtD
Toremifene—Dermatitis—Thiotepa—urinary bladder cancer	0.000175	0.00164	CcSEcCtD
Toremifene—Headache—Thiotepa—urinary bladder cancer	0.000174	0.00163	CcSEcCtD
Toremifene—Decreased appetite—Etoposide—urinary bladder cancer	0.000173	0.00163	CcSEcCtD
Toremifene—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000172	0.00162	CcSEcCtD
Toremifene—Fatigue—Etoposide—urinary bladder cancer	0.000172	0.00162	CcSEcCtD
Toremifene—Neuropathy peripheral—Epirubicin—urinary bladder cancer	0.000172	0.00161	CcSEcCtD
Toremifene—Jaundice—Epirubicin—urinary bladder cancer	0.000171	0.00161	CcSEcCtD
Toremifene—Pain—Etoposide—urinary bladder cancer	0.000171	0.0016	CcSEcCtD
Toremifene—Constipation—Etoposide—urinary bladder cancer	0.000171	0.0016	CcSEcCtD
Toremifene—Sweating—Epirubicin—urinary bladder cancer	0.000168	0.00158	CcSEcCtD
Toremifene—Asthenia—Gemcitabine—urinary bladder cancer	0.000168	0.00157	CcSEcCtD
Toremifene—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.000166	0.00156	CcSEcCtD
Toremifene—Weight increased—Doxorubicin—urinary bladder cancer	0.000166	0.00156	CcSEcCtD
Toremifene—Pruritus—Gemcitabine—urinary bladder cancer	0.000165	0.00155	CcSEcCtD
Toremifene—Nausea—Thiotepa—urinary bladder cancer	0.000165	0.00155	CcSEcCtD
Toremifene—Pruritus—Fluorouracil—urinary bladder cancer	0.000163	0.00153	CcSEcCtD
Toremifene—Visual impairment—Methotrexate—urinary bladder cancer	0.000162	0.00152	CcSEcCtD
Toremifene—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000159	0.00149	CcSEcCtD
Toremifene—Jaundice—Doxorubicin—urinary bladder cancer	0.000158	0.00149	CcSEcCtD
Toremifene—Eye disorder—Methotrexate—urinary bladder cancer	0.000157	0.00148	CcSEcCtD
Toremifene—Asthenia—Cisplatin—urinary bladder cancer	0.000156	0.00147	CcSEcCtD
Toremifene—Sweating—Doxorubicin—urinary bladder cancer	0.000156	0.00146	CcSEcCtD
Toremifene—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000153	0.00144	CcSEcCtD
Toremifene—Angiopathy—Methotrexate—urinary bladder cancer	0.000153	0.00143	CcSEcCtD
Toremifene—Dizziness—Fluorouracil—urinary bladder cancer	0.000152	0.00143	CcSEcCtD
Toremifene—Visual impairment—Epirubicin—urinary bladder cancer	0.000152	0.00143	CcSEcCtD
Toremifene—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000152	0.00142	CcSEcCtD
Toremifene—Chills—Methotrexate—urinary bladder cancer	0.000151	0.00142	CcSEcCtD
Toremifene—Alopecia—Methotrexate—urinary bladder cancer	0.000149	0.0014	CcSEcCtD
Toremifene—Vomiting—Gemcitabine—urinary bladder cancer	0.000149	0.0014	CcSEcCtD
Toremifene—Mental disorder—Methotrexate—urinary bladder cancer	0.000147	0.00138	CcSEcCtD
Toremifene—Rash—Gemcitabine—urinary bladder cancer	0.000147	0.00138	CcSEcCtD
Toremifene—Dermatitis—Gemcitabine—urinary bladder cancer	0.000147	0.00138	CcSEcCtD
Toremifene—Eye disorder—Epirubicin—urinary bladder cancer	0.000147	0.00138	CcSEcCtD
Toremifene—Malnutrition—Methotrexate—urinary bladder cancer	0.000146	0.00138	CcSEcCtD
Toremifene—Headache—Gemcitabine—urinary bladder cancer	0.000146	0.00137	CcSEcCtD
Toremifene—Vomiting—Fluorouracil—urinary bladder cancer	0.000146	0.00137	CcSEcCtD
Toremifene—Rash—Fluorouracil—urinary bladder cancer	0.000145	0.00136	CcSEcCtD
Toremifene—Dermatitis—Fluorouracil—urinary bladder cancer	0.000145	0.00136	CcSEcCtD
Toremifene—Headache—Fluorouracil—urinary bladder cancer	0.000144	0.00135	CcSEcCtD
Toremifene—Asthenia—Etoposide—urinary bladder cancer	0.000143	0.00134	CcSEcCtD
Toremifene—Angiopathy—Epirubicin—urinary bladder cancer	0.000143	0.00134	CcSEcCtD
Toremifene—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000142	0.00133	CcSEcCtD
Toremifene—Back pain—Methotrexate—urinary bladder cancer	0.000142	0.00133	CcSEcCtD
Toremifene—Chills—Epirubicin—urinary bladder cancer	0.000141	0.00133	CcSEcCtD
Toremifene—Pruritus—Etoposide—urinary bladder cancer	0.000141	0.00133	CcSEcCtD
Toremifene—Arrhythmia—Epirubicin—urinary bladder cancer	0.000141	0.00132	CcSEcCtD
Toremifene—Visual impairment—Doxorubicin—urinary bladder cancer	0.00014	0.00132	CcSEcCtD
Toremifene—Alopecia—Epirubicin—urinary bladder cancer	0.000139	0.00131	CcSEcCtD
Toremifene—Nausea—Gemcitabine—urinary bladder cancer	0.000139	0.0013	CcSEcCtD
Toremifene—Vomiting—Cisplatin—urinary bladder cancer	0.000138	0.0013	CcSEcCtD
Toremifene—Vision blurred—Methotrexate—urinary bladder cancer	0.000138	0.0013	CcSEcCtD
Toremifene—Mental disorder—Epirubicin—urinary bladder cancer	0.000138	0.0013	CcSEcCtD
Toremifene—Rash—Cisplatin—urinary bladder cancer	0.000137	0.00129	CcSEcCtD
Toremifene—Dermatitis—Cisplatin—urinary bladder cancer	0.000137	0.00129	CcSEcCtD
Toremifene—Malnutrition—Epirubicin—urinary bladder cancer	0.000137	0.00129	CcSEcCtD
Toremifene—Nausea—Fluorouracil—urinary bladder cancer	0.000136	0.00128	CcSEcCtD
Toremifene—Eye disorder—Doxorubicin—urinary bladder cancer	0.000136	0.00128	CcSEcCtD
Toremifene—Back pain—Epirubicin—urinary bladder cancer	0.000133	0.00125	CcSEcCtD
Toremifene—Angiopathy—Doxorubicin—urinary bladder cancer	0.000132	0.00124	CcSEcCtD
Toremifene—Dizziness—Etoposide—urinary bladder cancer	0.000132	0.00124	CcSEcCtD
Toremifene—Vertigo—Methotrexate—urinary bladder cancer	0.000132	0.00124	CcSEcCtD
Toremifene—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000131	0.00123	CcSEcCtD
Toremifene—Leukopenia—Methotrexate—urinary bladder cancer	0.000131	0.00123	CcSEcCtD
Toremifene—Chills—Doxorubicin—urinary bladder cancer	0.000131	0.00123	CcSEcCtD
Toremifene—Arrhythmia—Doxorubicin—urinary bladder cancer	0.00013	0.00122	CcSEcCtD
Toremifene—Nausea—Cisplatin—urinary bladder cancer	0.000129	0.00122	CcSEcCtD
Toremifene—Vision blurred—Epirubicin—urinary bladder cancer	0.000129	0.00121	CcSEcCtD
Toremifene—Alopecia—Doxorubicin—urinary bladder cancer	0.000129	0.00121	CcSEcCtD
Toremifene—Mental disorder—Doxorubicin—urinary bladder cancer	0.000128	0.0012	CcSEcCtD
Toremifene—Vomiting—Etoposide—urinary bladder cancer	0.000127	0.00119	CcSEcCtD
Toremifene—Malnutrition—Doxorubicin—urinary bladder cancer	0.000127	0.00119	CcSEcCtD
Toremifene—Rash—Etoposide—urinary bladder cancer	0.000126	0.00118	CcSEcCtD
Toremifene—Dermatitis—Etoposide—urinary bladder cancer	0.000126	0.00118	CcSEcCtD
Toremifene—Headache—Etoposide—urinary bladder cancer	0.000125	0.00117	CcSEcCtD
Toremifene—Chest pain—Methotrexate—urinary bladder cancer	0.000125	0.00117	CcSEcCtD
Toremifene—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000124	0.00116	CcSEcCtD
Toremifene—Vertigo—Epirubicin—urinary bladder cancer	0.000123	0.00116	CcSEcCtD
Toremifene—Leukopenia—Epirubicin—urinary bladder cancer	0.000123	0.00115	CcSEcCtD
Toremifene—Back pain—Doxorubicin—urinary bladder cancer	0.000123	0.00115	CcSEcCtD
Toremifene—ABCB1—lymph node—urinary bladder cancer	0.000121	0.00894	CbGeAlD
Toremifene—Vision blurred—Doxorubicin—urinary bladder cancer	0.000119	0.00112	CcSEcCtD
Toremifene—Nausea—Etoposide—urinary bladder cancer	0.000118	0.00111	CcSEcCtD
Toremifene—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000117	0.0011	CcSEcCtD
Toremifene—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000117	0.0011	CcSEcCtD
Toremifene—Chest pain—Epirubicin—urinary bladder cancer	0.000117	0.0011	CcSEcCtD
Toremifene—Skin disorder—Methotrexate—urinary bladder cancer	0.000116	0.00109	CcSEcCtD
Toremifene—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000116	0.00109	CcSEcCtD
Toremifene—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000116	0.00109	CcSEcCtD
Toremifene—Vertigo—Doxorubicin—urinary bladder cancer	0.000114	0.00107	CcSEcCtD
Toremifene—Anorexia—Methotrexate—urinary bladder cancer	0.000114	0.00107	CcSEcCtD
Toremifene—Leukopenia—Doxorubicin—urinary bladder cancer	0.000113	0.00107	CcSEcCtD
Toremifene—Oedema—Epirubicin—urinary bladder cancer	0.000112	0.00105	CcSEcCtD
Toremifene—Nervous system disorder—Epirubicin—urinary bladder cancer	0.00011	0.00103	CcSEcCtD
Toremifene—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000109	0.00103	CcSEcCtD
Toremifene—Skin disorder—Epirubicin—urinary bladder cancer	0.000109	0.00102	CcSEcCtD
Toremifene—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000108	0.00102	CcSEcCtD
Toremifene—Insomnia—Methotrexate—urinary bladder cancer	0.000108	0.00102	CcSEcCtD
Toremifene—Chest pain—Doxorubicin—urinary bladder cancer	0.000108	0.00101	CcSEcCtD
Toremifene—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000107	0.00101	CcSEcCtD
Toremifene—Anorexia—Epirubicin—urinary bladder cancer	0.000107	0.001	CcSEcCtD
Toremifene—Dyspnoea—Methotrexate—urinary bladder cancer	0.000107	0.001	CcSEcCtD
Toremifene—Decreased appetite—Methotrexate—urinary bladder cancer	0.000104	0.000976	CcSEcCtD
Toremifene—Oedema—Doxorubicin—urinary bladder cancer	0.000103	0.000972	CcSEcCtD
Toremifene—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000103	0.000969	CcSEcCtD
Toremifene—Fatigue—Methotrexate—urinary bladder cancer	0.000103	0.000968	CcSEcCtD
Toremifene—Pain—Methotrexate—urinary bladder cancer	0.000102	0.00096	CcSEcCtD
Toremifene—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000101	0.000953	CcSEcCtD
Toremifene—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000101	0.000952	CcSEcCtD
Toremifene—Insomnia—Epirubicin—urinary bladder cancer	0.000101	0.00095	CcSEcCtD
Toremifene—Skin disorder—Doxorubicin—urinary bladder cancer	0.0001	0.000944	CcSEcCtD
Toremifene—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.0001	0.00094	CcSEcCtD
Toremifene—Dyspnoea—Epirubicin—urinary bladder cancer	9.97e-05	0.000937	CcSEcCtD
Toremifene—Anorexia—Doxorubicin—urinary bladder cancer	9.86e-05	0.000927	CcSEcCtD
Toremifene—Decreased appetite—Epirubicin—urinary bladder cancer	9.72e-05	0.000913	CcSEcCtD
Toremifene—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	9.65e-05	0.000907	CcSEcCtD
Toremifene—Fatigue—Epirubicin—urinary bladder cancer	9.64e-05	0.000906	CcSEcCtD
Toremifene—Pain—Epirubicin—urinary bladder cancer	9.56e-05	0.000898	CcSEcCtD
Toremifene—Constipation—Epirubicin—urinary bladder cancer	9.56e-05	0.000898	CcSEcCtD
Toremifene—Insomnia—Doxorubicin—urinary bladder cancer	9.36e-05	0.000879	CcSEcCtD
Toremifene—Dyspnoea—Doxorubicin—urinary bladder cancer	9.22e-05	0.000867	CcSEcCtD
Toremifene—Decreased appetite—Doxorubicin—urinary bladder cancer	8.99e-05	0.000845	CcSEcCtD
Toremifene—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	8.93e-05	0.000839	CcSEcCtD
Toremifene—Fatigue—Doxorubicin—urinary bladder cancer	8.92e-05	0.000838	CcSEcCtD
Toremifene—Constipation—Doxorubicin—urinary bladder cancer	8.85e-05	0.000831	CcSEcCtD
Toremifene—Pain—Doxorubicin—urinary bladder cancer	8.85e-05	0.000831	CcSEcCtD
Toremifene—Asthenia—Methotrexate—urinary bladder cancer	8.57e-05	0.000805	CcSEcCtD
Toremifene—Pruritus—Methotrexate—urinary bladder cancer	8.45e-05	0.000794	CcSEcCtD
Toremifene—Asthenia—Epirubicin—urinary bladder cancer	8.02e-05	0.000754	CcSEcCtD
Toremifene—Pruritus—Epirubicin—urinary bladder cancer	7.91e-05	0.000743	CcSEcCtD
Toremifene—Dizziness—Methotrexate—urinary bladder cancer	7.9e-05	0.000742	CcSEcCtD
Toremifene—Vomiting—Methotrexate—urinary bladder cancer	7.6e-05	0.000714	CcSEcCtD
Toremifene—Rash—Methotrexate—urinary bladder cancer	7.53e-05	0.000708	CcSEcCtD
Toremifene—Dermatitis—Methotrexate—urinary bladder cancer	7.53e-05	0.000707	CcSEcCtD
Toremifene—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	7.49e-05	0.00109	CbGpPWpGaD
Toremifene—Headache—Methotrexate—urinary bladder cancer	7.49e-05	0.000703	CcSEcCtD
Toremifene—Asthenia—Doxorubicin—urinary bladder cancer	7.42e-05	0.000697	CcSEcCtD
Toremifene—Dizziness—Epirubicin—urinary bladder cancer	7.39e-05	0.000695	CcSEcCtD
Toremifene—CYP1A2—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	7.36e-05	0.00107	CbGpPWpGaD
Toremifene—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—NCOR1—urinary bladder cancer	7.35e-05	0.00107	CbGpPWpGaD
Toremifene—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CREBBP—urinary bladder cancer	7.34e-05	0.00107	CbGpPWpGaD
Toremifene—ESR1—Signaling by ERBB4—ERBB2—urinary bladder cancer	7.32e-05	0.00106	CbGpPWpGaD
Toremifene—Pruritus—Doxorubicin—urinary bladder cancer	7.32e-05	0.000688	CcSEcCtD
Toremifene—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—urinary bladder cancer	7.29e-05	0.00106	CbGpPWpGaD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	7.28e-05	0.00106	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	7.25e-05	0.00105	CbGpPWpGaD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	7.19e-05	0.00105	CbGpPWpGaD
Toremifene—ESR1—Leptin signaling pathway—HRAS—urinary bladder cancer	7.17e-05	0.00104	CbGpPWpGaD
Toremifene—Vomiting—Epirubicin—urinary bladder cancer	7.11e-05	0.000668	CcSEcCtD
Toremifene—Nausea—Methotrexate—urinary bladder cancer	7.1e-05	0.000667	CcSEcCtD
Toremifene—Rash—Epirubicin—urinary bladder cancer	7.05e-05	0.000662	CcSEcCtD
Toremifene—Dermatitis—Epirubicin—urinary bladder cancer	7.04e-05	0.000662	CcSEcCtD
Toremifene—CYP1A1—Aryl Hydrocarbon Receptor—HRAS—urinary bladder cancer	7.02e-05	0.00102	CbGpPWpGaD
Toremifene—Headache—Epirubicin—urinary bladder cancer	7.01e-05	0.000658	CcSEcCtD
Toremifene—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—urinary bladder cancer	6.88e-05	0.001	CbGpPWpGaD
Toremifene—Dizziness—Doxorubicin—urinary bladder cancer	6.84e-05	0.000643	CcSEcCtD
Toremifene—ESR1—Generic Transcription Pathway—ESR2—urinary bladder cancer	6.81e-05	0.000989	CbGpPWpGaD
Toremifene—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—urinary bladder cancer	6.79e-05	0.000987	CbGpPWpGaD
Toremifene—Nausea—Epirubicin—urinary bladder cancer	6.64e-05	0.000624	CcSEcCtD
Toremifene—Vomiting—Doxorubicin—urinary bladder cancer	6.58e-05	0.000618	CcSEcCtD
Toremifene—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—urinary bladder cancer	6.54e-05	0.000951	CbGpPWpGaD
Toremifene—CYP1A2—Aryl Hydrocarbon Receptor—EP300—urinary bladder cancer	6.54e-05	0.000951	CbGpPWpGaD
Toremifene—Rash—Doxorubicin—urinary bladder cancer	6.52e-05	0.000613	CcSEcCtD
Toremifene—Dermatitis—Doxorubicin—urinary bladder cancer	6.52e-05	0.000612	CcSEcCtD
Toremifene—ESR1—Integrated Breast Cancer Pathway—CCND1—urinary bladder cancer	6.5e-05	0.000945	CbGpPWpGaD
Toremifene—Headache—Doxorubicin—urinary bladder cancer	6.48e-05	0.000609	CcSEcCtD
Toremifene—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—urinary bladder cancer	6.36e-05	0.000925	CbGpPWpGaD
Toremifene—CYP1A2—Aryl Hydrocarbon Receptor—SRC—urinary bladder cancer	6.36e-05	0.000925	CbGpPWpGaD
Toremifene—ESR1—Integrated Breast Cancer Pathway—PTEN—urinary bladder cancer	6.28e-05	0.000912	CbGpPWpGaD
Toremifene—ESR1—Signaling by ERBB4—CDKN1A—urinary bladder cancer	6.26e-05	0.00091	CbGpPWpGaD
Toremifene—ESR1—Signaling by ERBB4—PTEN—urinary bladder cancer	6.24e-05	0.000908	CbGpPWpGaD
Toremifene—ABCB1—Allograft Rejection—CXCL8—urinary bladder cancer	6.2e-05	0.000901	CbGpPWpGaD
Toremifene—Nausea—Doxorubicin—urinary bladder cancer	6.15e-05	0.000577	CcSEcCtD
Toremifene—ABCB1—HIF-1-alpha transcription factor network—EP300—urinary bladder cancer	6.14e-05	0.000893	CbGpPWpGaD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	6.1e-05	0.000887	CbGpPWpGaD
Toremifene—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	6.07e-05	0.000882	CbGpPWpGaD
Toremifene—ESR1—Integrated Breast Cancer Pathway—EP300—urinary bladder cancer	5.99e-05	0.00087	CbGpPWpGaD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	5.96e-05	0.000867	CbGpPWpGaD
Toremifene—ABCB1—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	5.94e-05	0.000863	CbGpPWpGaD
Toremifene—ABCB1—Allograft Rejection—IL2—urinary bladder cancer	5.93e-05	0.000861	CbGpPWpGaD
Toremifene—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	5.89e-05	0.000856	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	5.77e-05	0.000838	CbGpPWpGaD
Toremifene—CYP1A2—Aryl Hydrocarbon Receptor—MYC—urinary bladder cancer	5.7e-05	0.000829	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	5.68e-05	0.000825	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	5.66e-05	0.000823	CbGpPWpGaD
Toremifene—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—urinary bladder cancer	5.58e-05	0.000811	CbGpPWpGaD
Toremifene—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—urinary bladder cancer	5.58e-05	0.000811	CbGpPWpGaD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	5.39e-05	0.000783	CbGpPWpGaD
Toremifene—CYP1A2—Aryl Hydrocarbon Receptor—TNF—urinary bladder cancer	5.31e-05	0.000772	CbGpPWpGaD
Toremifene—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—urinary bladder cancer	5.31e-05	0.000772	CbGpPWpGaD
Toremifene—CYP1A2—Biological oxidations—GSTP1—urinary bladder cancer	5.29e-05	0.000769	CbGpPWpGaD
Toremifene—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—urinary bladder cancer	5.27e-05	0.000766	CbGpPWpGaD
Toremifene—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—urinary bladder cancer	5.27e-05	0.000765	CbGpPWpGaD
Toremifene—ESR1—Generic Transcription Pathway—NCOR1—urinary bladder cancer	5.26e-05	0.000764	CbGpPWpGaD
Toremifene—ESR1—Integrated Breast Cancer Pathway—MYC—urinary bladder cancer	5.22e-05	0.000758	CbGpPWpGaD
Toremifene—CYP1A2—Metapathway biotransformation—GSTP1—urinary bladder cancer	5.22e-05	0.000758	CbGpPWpGaD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	5.21e-05	0.000758	CbGpPWpGaD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	5.2e-05	0.000756	CbGpPWpGaD
Toremifene—CYP1A1—PPARA activates gene expression—EP300—urinary bladder cancer	5.11e-05	0.000743	CbGpPWpGaD
Toremifene—ESR1—Integrated Breast Cancer Pathway—EGFR—urinary bladder cancer	5.1e-05	0.000742	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—GSTZ1—urinary bladder cancer	5.08e-05	0.000738	CbGpPWpGaD
Toremifene—ESR1—Signaling by ERBB4—EGFR—urinary bladder cancer	5.08e-05	0.000738	CbGpPWpGaD
Toremifene—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—CREBBP—urinary bladder cancer	5.06e-05	0.000735	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	5.02e-05	0.000729	CbGpPWpGaD
Toremifene—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—urinary bladder cancer	5e-05	0.000727	CbGpPWpGaD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	4.96e-05	0.000721	CbGpPWpGaD
Toremifene—CYP1A2—Biological oxidations—GSTM1—urinary bladder cancer	4.86e-05	0.000706	CbGpPWpGaD
Toremifene—ABCB1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	4.84e-05	0.000704	CbGpPWpGaD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	4.82e-05	0.000701	CbGpPWpGaD
Toremifene—ESR1—Integrated Breast Cancer Pathway—KRAS—urinary bladder cancer	4.82e-05	0.000701	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—NAT1—urinary bladder cancer	4.82e-05	0.0007	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—GSTO2—urinary bladder cancer	4.82e-05	0.0007	CbGpPWpGaD
Toremifene—ESR1—Signaling by ERBB4—KRAS—urinary bladder cancer	4.8e-05	0.000697	CbGpPWpGaD
Toremifene—CYP1A2—Metapathway biotransformation—GSTM1—urinary bladder cancer	4.79e-05	0.000697	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	4.74e-05	0.000688	CbGpPWpGaD
Toremifene—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—urinary bladder cancer	4.48e-05	0.000651	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	4.43e-05	0.000644	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	4.42e-05	0.000642	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—UGT2B7—urinary bladder cancer	4.41e-05	0.00064	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	4.4e-05	0.000639	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—HDAC4—urinary bladder cancer	4.4e-05	0.000639	CbGpPWpGaD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	4.32e-05	0.000628	CbGpPWpGaD
Toremifene—ABCB1—Allograft Rejection—TNF—urinary bladder cancer	4.32e-05	0.000627	CbGpPWpGaD
Toremifene—ESR1—Integrated Breast Cancer Pathway—TP53—urinary bladder cancer	4.28e-05	0.000623	CbGpPWpGaD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	4.23e-05	0.000614	CbGpPWpGaD
Toremifene—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	4.08e-05	0.000593	CbGpPWpGaD
Toremifene—ESR1—Signaling by ERBB4—HRAS—urinary bladder cancer	4.08e-05	0.000592	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—GSTZ1—urinary bladder cancer	4.06e-05	0.00059	CbGpPWpGaD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	4.03e-05	0.000585	CbGpPWpGaD
Toremifene—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	4.03e-05	0.000585	CbGpPWpGaD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	3.99e-05	0.00058	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—CYP4B1—urinary bladder cancer	3.97e-05	0.000576	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	3.85e-05	0.00056	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—GSTO2—urinary bladder cancer	3.85e-05	0.000559	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—NAT1—urinary bladder cancer	3.85e-05	0.000559	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	3.81e-05	0.000553	CbGpPWpGaD
Toremifene—ESR1—Generic Transcription Pathway—PPARG—urinary bladder cancer	3.77e-05	0.000547	CbGpPWpGaD
Toremifene—ESR1—Gene Expression—SMC1A—urinary bladder cancer	3.76e-05	0.000547	CbGpPWpGaD
Toremifene—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	3.75e-05	0.000545	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—SLC19A1—urinary bladder cancer	3.75e-05	0.000544	CbGpPWpGaD
Toremifene—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	3.7e-05	0.000538	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—GLI1—urinary bladder cancer	3.68e-05	0.000535	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—PRSS3—urinary bladder cancer	3.65e-05	0.00053	CbGpPWpGaD
Toremifene—ESR1—Generic Transcription Pathway—CREBBP—urinary bladder cancer	3.62e-05	0.000526	CbGpPWpGaD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	3.55e-05	0.000516	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—UGT2B7—urinary bladder cancer	3.52e-05	0.000511	CbGpPWpGaD
Toremifene—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—urinary bladder cancer	3.45e-05	0.000501	CbGpPWpGaD
Toremifene—ESR1—Gene Expression—ESR2—urinary bladder cancer	3.28e-05	0.000476	CbGpPWpGaD
Toremifene—ABCB1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	3.27e-05	0.000475	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—GSTZ1—urinary bladder cancer	3.24e-05	0.000471	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	3.23e-05	0.000469	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—CYP4B1—urinary bladder cancer	3.17e-05	0.00046	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	3.16e-05	0.000459	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—GSTO2—urinary bladder cancer	3.07e-05	0.000446	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—NAT1—urinary bladder cancer	3.07e-05	0.000446	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	3.02e-05	0.000439	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—SLC19A1—urinary bladder cancer	2.99e-05	0.000435	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.93e-05	0.000425	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—TYMP—urinary bladder cancer	2.92e-05	0.000424	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—PRSS3—urinary bladder cancer	2.92e-05	0.000424	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	2.85e-05	0.000414	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—UGT2B7—urinary bladder cancer	2.81e-05	0.000408	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.8e-05	0.000407	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	2.76e-05	0.000401	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	2.75e-05	0.0004	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—NAT2—urinary bladder cancer	2.64e-05	0.000384	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	2.62e-05	0.000381	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	2.55e-05	0.000371	CbGpPWpGaD
Toremifene—ESR1—Gene Expression—NCOR1—urinary bladder cancer	2.53e-05	0.000368	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—CYP4B1—urinary bladder cancer	2.53e-05	0.000368	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—RBX1—urinary bladder cancer	2.52e-05	0.000367	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	2.5e-05	0.000363	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—SLC19A1—urinary bladder cancer	2.39e-05	0.000347	CbGpPWpGaD
Toremifene—ESR1—Gene Expression—ERCC2—urinary bladder cancer	2.38e-05	0.000346	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—TSC1—urinary bladder cancer	2.37e-05	0.000345	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	2.37e-05	0.000344	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—NAT1—urinary bladder cancer	2.37e-05	0.000344	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—TYMP—urinary bladder cancer	2.33e-05	0.000339	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—PRSS3—urinary bladder cancer	2.33e-05	0.000338	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	2.29e-05	0.000332	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—RRM2—urinary bladder cancer	2.28e-05	0.000331	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—JAG1—urinary bladder cancer	2.26e-05	0.000328	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	2.24e-05	0.000325	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	2.17e-05	0.000315	CbGpPWpGaD
Toremifene—ESR1—Generic Transcription Pathway—MYC—urinary bladder cancer	2.15e-05	0.000312	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	2.13e-05	0.00031	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	2.11e-05	0.000307	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—HPGDS—urinary bladder cancer	2.11e-05	0.000307	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—ENO2—urinary bladder cancer	2.11e-05	0.000307	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—NAT2—urinary bladder cancer	2.11e-05	0.000306	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.1e-05	0.000305	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—GSTT1—urinary bladder cancer	2.05e-05	0.000297	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.01e-05	0.000293	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	1.95e-05	0.000284	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	1.88e-05	0.000273	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.87e-05	0.000271	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—TYMP—urinary bladder cancer	1.86e-05	0.00027	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	1.84e-05	0.000268	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—S100B—urinary bladder cancer	1.83e-05	0.000266	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—RRM2—urinary bladder cancer	1.82e-05	0.000264	CbGpPWpGaD
Toremifene—ESR1—Gene Expression—PPARG—urinary bladder cancer	1.81e-05	0.000264	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	1.8e-05	0.000261	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.79e-05	0.00026	CbGpPWpGaD
Toremifene—ESR1—Gene Expression—CREBBP—urinary bladder cancer	1.74e-05	0.000253	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—NQO1—urinary bladder cancer	1.7e-05	0.000247	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—HPGDS—urinary bladder cancer	1.69e-05	0.000245	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—ENO2—urinary bladder cancer	1.69e-05	0.000245	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—NAT2—urinary bladder cancer	1.68e-05	0.000245	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.65e-05	0.00024	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—NCOR1—urinary bladder cancer	1.65e-05	0.000239	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—GSTT1—urinary bladder cancer	1.63e-05	0.000238	CbGpPWpGaD
Toremifene—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.53e-05	0.000222	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—RRM2—urinary bladder cancer	1.45e-05	0.000211	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—TERT—urinary bladder cancer	1.45e-05	0.000211	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.44e-05	0.000209	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—TYMP—urinary bladder cancer	1.44e-05	0.000209	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—GSTP1—urinary bladder cancer	1.42e-05	0.000206	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.37e-05	0.000199	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—NQO1—urinary bladder cancer	1.36e-05	0.000197	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	1.35e-05	0.000195	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—ENO2—urinary bladder cancer	1.35e-05	0.000195	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.34e-05	0.000194	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—FGFR3—urinary bladder cancer	1.33e-05	0.000193	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—TYMS—urinary bladder cancer	1.32e-05	0.000192	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	1.3e-05	0.00019	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—GSTM1—urinary bladder cancer	1.3e-05	0.000189	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—NCOR1—urinary bladder cancer	1.3e-05	0.000189	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—NAT2—urinary bladder cancer	1.3e-05	0.000189	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.28e-05	0.000187	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—GPX1—urinary bladder cancer	1.25e-05	0.000181	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—ERCC2—urinary bladder cancer	1.23e-05	0.000178	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—MTHFR—urinary bladder cancer	1.15e-05	0.000167	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—GSTP1—urinary bladder cancer	1.13e-05	0.000165	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—CREBBP—urinary bladder cancer	1.13e-05	0.000165	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—RRM2—urinary bladder cancer	1.12e-05	0.000163	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—IGF1—urinary bladder cancer	1.12e-05	0.000163	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—NQO1—urinary bladder cancer	1.08e-05	0.000158	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—TYMS—urinary bladder cancer	1.05e-05	0.000153	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.05e-05	0.000153	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—GSTM1—urinary bladder cancer	1.04e-05	0.000151	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—NCOR1—urinary bladder cancer	1.04e-05	0.000151	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.04e-05	0.000151	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.04e-05	0.000151	CbGpPWpGaD
Toremifene—ESR1—Gene Expression—MYC—urinary bladder cancer	1.03e-05	0.00015	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—RHOA—urinary bladder cancer	1.02e-05	0.000149	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1.01e-05	0.000146	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—GPX1—urinary bladder cancer	9.97e-06	0.000145	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—ERCC2—urinary bladder cancer	9.79e-06	0.000142	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—ERBB2—urinary bladder cancer	9.49e-06	0.000138	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—PPARG—urinary bladder cancer	9.34e-06	0.000136	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—MTHFR—urinary bladder cancer	9.2e-06	0.000134	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	9.17e-06	0.000133	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	9.04e-06	0.000131	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—CXCL8—urinary bladder cancer	9e-06	0.000131	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—CREBBP—urinary bladder cancer	8.97e-06	0.00013	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	8.75e-06	0.000127	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—IL2—urinary bladder cancer	8.6e-06	0.000125	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—TYMS—urinary bladder cancer	8.41e-06	0.000122	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—CCND1—urinary bladder cancer	8.38e-06	0.000122	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—NQO1—urinary bladder cancer	8.37e-06	0.000122	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	8.31e-06	0.000121	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	8.31e-06	0.000121	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—MMP9—urinary bladder cancer	8.14e-06	0.000118	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—CDKN1A—urinary bladder cancer	8.11e-06	0.000118	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—PTEN—urinary bladder cancer	8.09e-06	0.000118	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—GPX1—urinary bladder cancer	7.96e-06	0.000116	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	7.81e-06	0.000114	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—EP300—urinary bladder cancer	7.71e-06	0.000112	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—SRC—urinary bladder cancer	7.5e-06	0.000109	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—PPARG—urinary bladder cancer	7.46e-06	0.000108	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—PTGS2—urinary bladder cancer	7.35e-06	0.000107	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	7.34e-06	0.000107	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—CREBBP—urinary bladder cancer	7.17e-06	0.000104	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	6.98e-06	0.000101	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—MYC—urinary bladder cancer	6.72e-06	9.77e-05	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—EGFR—urinary bladder cancer	6.57e-06	9.56e-05	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—TYMS—urinary bladder cancer	6.49e-06	9.43e-05	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	6.41e-06	9.32e-05	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	6.41e-06	9.32e-05	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—PTEN—urinary bladder cancer	6.41e-06	9.31e-05	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—KRAS—urinary bladder cancer	6.21e-06	9.03e-05	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—GPX1—urinary bladder cancer	6.14e-06	8.93e-05	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—EP300—urinary bladder cancer	6.11e-06	8.88e-05	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	6.03e-06	8.76e-05	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—PPARG—urinary bladder cancer	5.96e-06	8.66e-05	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—PTGS2—urinary bladder cancer	5.87e-06	8.53e-05	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	5.72e-06	8.31e-05	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	5.67e-06	8.24e-05	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—TP53—urinary bladder cancer	5.52e-06	8.02e-05	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—HRAS—urinary bladder cancer	5.28e-06	7.67e-05	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—PTEN—urinary bladder cancer	5.12e-06	7.44e-05	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—EP300—urinary bladder cancer	4.88e-06	7.09e-05	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	4.69e-06	6.81e-05	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—PPARG—urinary bladder cancer	4.6e-06	6.68e-05	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	4.42e-06	6.42e-05	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—PTEN—urinary bladder cancer	4.09e-06	5.94e-05	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—EP300—urinary bladder cancer	3.9e-06	5.66e-05	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	3.62e-06	5.25e-05	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—PTEN—urinary bladder cancer	3.15e-06	4.58e-05	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—EP300—urinary bladder cancer	3.01e-06	4.37e-05	CbGpPWpGaD
